Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.
Reuters NewMedia - December 13, 2004
If the company also wins approval for the drugs themselves, it could pave the way for it to supply anti-retrovirals to a U.S. government $15 billion AIDS funding programme.
The stock gained 5.56 percent to 19.00 rand by 0726 GMT, making it the third biggest gainer on the South African bourse as it outperformed a slightly stronger Johannesburg all-share index.
The company said in a statement it was the first African company to win approval from the U.S. Food and Drug Administration for a factory to produce the anti-retroviral drugs.
The United States must first approve any of the generic drugs before using them under its own funding programmes.
Aspen will make the drugs at its plant in Port Elizabeth, and hopes to clinch final FDA approval for the drugs themselves in early 2005.
041213
RE041242
Copyright © 2004 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .